Cosmetic Insights &
Industry Trends.
Discover expert articles on makeup formulation, OEM innovations, and global beauty events.
Color Cosmetics
Excellence.
Stay informed with cutting-edge developments from our Milan R&D laboratories.
Pioneering
Beauty Solutions.
Exploring next-generation applicators, sustainability, and private label growth strategies.
Top Cosmetic Formula Development Companies in China?
Table of Contents
- Cosmetic Formula Development in China: Scope, Services, and NMPA Categories
- China’s Cosmetics Retail Sales Reached RMB 414.2 Billion in 2023 (NBS)
- China Required Full Cosmetic Safety Assessment Reports from May 2025
- How to Compare Developers by R&D, GMP Readiness, Claims, and Scale
- Profiles of Leading Cosmetic Formula Development Companies in China
- FAQS
- Conclusion
- Related Posts
China’s beauty market rewards formulas that perform well on skin, remain stable in real-world use, and scale reliably from pilot batches to production. McKinsey’s 2023 beauty-market analysis projected global beauty sales could reach about $580 billion by 2027, with annual growth near 6%. That expansion raises the stakes for brands choosing development partners in China. A promising texture is only a start.
Cosmetic Formula Development combines ingredient selection, formulation, testing, and manufacturing readiness. China’s National Medical Products Administration has placed product quality and safety responsibilities on cosmetics registrants and record-filers under its Cosmetics Supervision and Administration Regulation. For buyers, that makes technical records and safety-assessment support practical selection criteria, not decorative extras. A glossy laboratory tour proves little. Ask how a company handles stability testing, compatibility checks, ingredient traceability, and scale-up when a formula behaves differently in a larger tank.
This guide compares leading Chinese development companies through their research capabilities, product categories, manufacturing support, and communication practices. It also considers whether a partner can explain trade-offs clearly, such as fragrance choices, preservation systems, or texture changes across batches. Company claims should be checked against available documentation and direct discussions. Not every supplier publishes comparable data, and rankings cannot capture every project’s needs. That limitation matters. A capable partner for a sunscreen may not suit a delicate facial serum, so brands should verify fit before committing.
Cosmetic Formula Development in China: Scope, Services, and NMPA Categories
Cosmetic formula development in China covers more than choosing ingredients. A development team may translate a brief into a prototype, then assess texture, scent, pH, and packaging compatibility. Stability checks can reveal changes after heat exposure or repeated opening. Useful records include test conditions, ingredient specifications, and formula revisions. Details matter.
Services often include ingredient screening, laboratory batches, safety documentation, efficacy testing, and production transfer. A cream that feels smooth in a sample jar may behave differently in a larger production tank. Teams should review mixing order, temperature, and filling conditions before scale-up. Results depend on the formula and test design; a single successful trial is not proof of long-term stability. This part can wobble.
China’s NMPA framework separates cosmetics into general and special categories. General cosmetics generally follow a filing process, while special cosmetics require registration before market entry. Special categories include hair dye, perm, freckle-removing and whitening, sunscreen, anti-hair-loss products, and products claiming new efficacy. Classification depends on product claims and intended use, not just its ingredients. Requirements can change, so developers should verify current NMPA guidance and keep supporting evidence aligned with the final formula and label.
Top Cosmetic Formula Development Companies in China? — Cosmetic Formula Development in China: Scope, Services, and NMPA Categories
| Development Area | Typical Scope and Services | Common Deliverables | NMPA Category or Regulatory Relevance | Practical Considerations |
|---|---|---|---|---|
| Product brief and concept | Translate intended use, target users, product format, sensory profile, and cost constraints into a technical development brief. | Product specification, preliminary ingredient strategy, development plan, and evaluation criteria. | Category selection depends on the product’s intended use and claims, not solely on its format or ingredient list. | Agree on claims and target market early; these can affect testing, labeling, and the regulatory pathway. |
| Formula research and prototyping | Develop and refine formulations such as emulsions, cleansers, lotions, creams, masks, and hair-care products; assess texture, fragrance, and application characteristics. | Laboratory prototypes, formula versions, ingredient specifications, and evaluation records. | Formula development should use ingredients permitted for the intended cosmetic use under applicable Chinese requirements. | Ingredient suitability, product stability, packaging compatibility, and manufacturing feasibility should be assessed together. |
| Ingredient and compliance review | Review ingredient names, intended functions, use conditions, supplier documentation, and applicable restrictions or specifications. | Ingredient review records, supporting-document checklist, and identified compliance questions. | China’s Inventory of Existing Cosmetic Ingredients in China (IECIC) and applicable safety and technical standards are relevant to ingredient review. | Ingredient status alone does not establish that a finished product is compliant; the formula, use conditions, and product documentation also matter. |
| Safety assessment support | Assemble formula, ingredient, exposure, and supporting safety information for the product safety assessment process. | Safety-assessment inputs, supporting evidence, and documentation gap list. | Cosmetic registrants and filing persons are responsible for product safety and required safety-assessment materials under China’s cosmetic regulatory framework. | Required evidence depends on the product and available data. Assessment should be completed by appropriately qualified personnel under current requirements. |
| Ordinary cosmetics | Develop products that do not fall within the special-cosmetics categories, subject to the product’s actual purpose and claims. | Formula and product documents to support the applicable filing and product-information requirements. | Ordinary cosmetics generally require filing with the competent authority before they are marketed in China; imported ordinary cosmetics are filed before import. | Filing obligations and supporting records should be confirmed for the specific product and responsible filing person. |
| Special cosmetics | Support formulation and technical documentation for products intended for regulated special purposes. | Formula information, supporting technical materials, and coordination inputs for the registration process. | Special cosmetics require registration before production or import. Categories include hair dye, hair perm, freckle-removing and whitening, sunscreen, anti-hair-loss cosmetics, and cosmetics claiming new efficacy. | Classification is determined by intended use and claims. Registration requirements should be checked against current NMPA rules before development decisions are finalized. |
| Claims and efficacy substantiation | Review proposed efficacy wording and identify an appropriate substantiation approach, which may include testing or other supporting evidence as applicable. | Claims review, evidence plan, and supporting-document checklist. | Claims must be supported by appropriate evidence and managed under applicable Chinese cosmetic claim and efficacy-evaluation requirements. | A claim can affect product classification. Avoid treating marketing language as separate from regulatory review. |
| Stability, compatibility, and testing | Plan or conduct relevant evaluations of product stability, packaging compatibility, and product quality characteristics. | Test plan, test samples, results, and follow-up recommendations, as applicable. | Testing and product documentation should align with applicable safety, technical, and filing or registration requirements. | Test scope and duration vary by formula, packaging, product type, and the evidence needed; no single schedule applies to every product. |
| Scale-up and manufacturing transfer | Adapt laboratory formulas for pilot or production-scale manufacture and review process parameters and quality controls. | Manufacturing instructions, process parameters, batch records, and quality-control recommendations. | Manufacturing and product responsibilities must align with applicable cosmetic production, quality, and regulatory requirements. | Scale-up can change product properties. Confirm that production batches remain consistent with the approved or filed product information. |
| New cosmetic ingredients | Assess whether a proposed ingredient is an existing cosmetic ingredient or may qualify as a new cosmetic ingredient, and identify the relevant documentation needs. | Ingredient status review, evidence-gap assessment, and regulatory planning inputs. | New cosmetic ingredients are subject to registration or filing requirements under China’s framework, depending on the ingredient and applicable rules. | Do not assume a new ingredient can be used in a finished product before its applicable regulatory requirements are met. |
Regulatory overview only. China’s requirements can change, and the applicable pathway depends on the product’s intended use, claims, ingredients, and market status. Confirm current requirements with the relevant authorities or qualified regulatory professionals.
China’s Cosmetics Retail Sales Reached RMB 414.2 Billion in 2023 (NBS)
China’s cosmetics retail sales reached RMB 414.2 billion in 2023, according to the National Bureau of Statistics (NBS). A substantial market. The figure signals considerable consumer spending, but it does not show which product categories drove sales. For formula developers, that distinction matters. Skincare, color cosmetics, and personal-care products can have very different needs for texture, stability, and packaging compatibility.
A large retail market can encourage product development, yet scale alone cannot guarantee a successful formula. A cream must spread evenly in humid weather; a cleanser should rinse clean without leaving skin feeling tight. Pilot batches can reveal issues that a lab sample misses, including changes in viscosity, fragrance, or color during storage. These checks need clear protocols and records. Small details matter.
When comparing cosmetic formula development companies in China, buyers can ask how teams translate consumer briefs into measurable specifications. Useful evidence includes stability-test records, repeatable batch documentation, ingredient traceability, and candid communication about limitations. The NBS sales total is a market indicator, not proof that every category is growing equally. It is tempting to read one large figure as a universal growth signal; that would be too simple. Demand creates opportunity, but careful testing and accurate product claims still shape what consumers choose again.
China Required Full Cosmetic Safety Assessment Reports from May 2025
China’s May 2025 safety-assessment deadline changes what a capable cosmetic formula development partner must deliver. From May 1, 2025, registrants and filers must submit a full safety assessment report for cosmetic registration or filing. NMPA’s Technical Guidelines for Cosmetic Safety Assessment call for evidence covering ingredients, exposure, toxicological profiles, and product use. A formula cannot be judged on its ingredient list alone.
The commercial stakes are substantial. iiMedia Research estimated China’s cosmetics market at about RMB 516.9 billion in 2023. That scale makes reliable documentation a practical requirement, not just a regulatory exercise. When evaluating development companies, ask how they trace raw-material specifications, review supplier safety data, and document assumptions for rinse-off or leave-on use. Request a sample report structure, with confidential details removed. Can the team explain why each key input is relevant?
Good partners also connect formulation work with stability testing and packaging compatibility. A cream may look uniform in a lab jar, yet separate after heat exposure or react with its closure. The assessment needs to reflect the product consumers will actually use. Small-data gaps still happen. A missing impurity profile can slow review, and the fix is rarely instant. Ask who owns each evidence gap, and how it will be closed before filing.
China Cosmetic Safety Assessment: Key Regulatory Milestones
A timeline of national safety-assessment requirements—not a ranking of cosmetic formula development companies.
What it means: China’s Cosmetic Safety Assessment Technical Guidelines (2021 edition) took effect on May 1, 2021. An NMPA notice published on December 31, 2023, extended the transition period for simplified assessment reports. From May 1, 2025, applicants are generally required to submit full safety assessment reports under the applicable requirements.
Sources: China NMPA, Cosmetic Safety Assessment Technical Guidelines (2021 edition) and notice on optimizing cosmetic safety assessment management (December 31, 2023).
How to Compare Developers by R&D, GMP Readiness, Claims, and Scale
Choosing a cosmetic formula developer in China takes more than comparing sample texture or quoted cost. Ask how the R&D team selects ingredients, adjusts prototypes, and documents decisions. Request records covering formulation rationale, stability observations, and packaging compatibility. Small details matter. A pleasant first sample may still change after weeks of storage.
GMP readiness should be checked through current procedures, training records, equipment maintenance, and batch documentation—not assumed from a brochure. Ask to review how raw materials are identified and how deviations are handled. Claims also need evidence. For example, a “long-lasting hydration” statement should connect to a suitable test and clear measurement method. Wording can sound convincing before the supporting data exists.
Scale is more than factory size. Discuss minimum order quantities, pilot batches, lead times, and how quality checks remain consistent when production grows. Ask who handles formula changes and what triggers a new review. A developer may be strong in laboratory work but less prepared for repeat production; that gap is easy to miss. Compare written answers with facility records, sample histories, and realistic timelines.
Profiles of Leading Cosmetic Formula Development Companies in China
Profiles of leading cosmetic formula development companies in China are best judged by their technical depth, not glossy sample books. The National Bureau of Statistics of China reported cosmetics retail sales of RMB 435.8 billion in 2024, up 2.8% year on year. That market scale raises expectations for consistent, production-ready formulas. Testing matters.
A strong profile should show how a team moves from brief to pilot batch: ingredient screening, emulsification trials, viscosity checks, and stability testing across temperature conditions. Ask how it documents formula versions and evaluates packaging compatibility. ISO 22716 offers a useful reference for good manufacturing practices, though a certificate alone does not prove a formula will perform well. Not every formula scales.
Some Chinese developers specialize in fast-turnaround skincare, while others focus on color cosmetics or sensory refinement. Look for in-house testing facilities, experienced formulators, and clear records of repeatability between laboratory and factory batches. Request anonymized case data, including stability duration and batch variation, rather than relying only on attractive textures. One limitation deserves attention: public information on development teams and testing methods can be sparse, so buyers may need to verify capabilities directly.
FAQS
Sales reached RMB 414.2 billion. This shows substantial consumer spending, but not which product categories drove it.
Market size creates opportunity, not guaranteed demand. A cream may spread differently in humid weather, while a cleanser may leave skin feeling tight.
Ask for stability observations, batch documentation, ingredient traceability, and packaging compatibility checks. A good-looking sample is not enough.
Review current procedures, staff training records, equipment maintenance, raw-material identification, and deviation handling. A brochure alone proves little.
Claims should connect to suitable tests and clear measurement methods. “Long-lasting hydration” sounds persuasive, but needs supporting data.
Discuss minimum order quantities, pilot batches, lead times, and consistent quality checks. Ask who reviews formula changes.
Request temperature-based stability results, viscosity checks, and packaging compatibility records. Weeks of storage can reveal changes in color or fragrance.
Look for ingredient screening, emulsification trials, experienced formulators, and repeatable laboratory and factory batches. Not every formula scales smoothly.
Cosmetics retail sales reached RMB 435.8 billion, up 2.8% year on year. That market scale does not prove every category is growing.
Public details about development teams and testing methods can be sparse. Buyers may need to request direct evidence and question gaps.
Conclusion
Cosmetic Formula Development in China covers the process of creating and refining products, from ingredient selection and testing to manufacturing preparation and regulatory documentation. The sector serves a large and growing market: China’s cosmetics retail sales reached RMB 414.2 billion in 2023, according to the National Bureau of Statistics. From May 2025, full cosmetic safety assessment reports are required, making robust safety work and documentation important parts of development planning.
When comparing Chinese formula developers, businesses can assess research and development capabilities, experience with relevant NMPA product categories, GMP readiness, support for substantiated product claims, and ability to scale production. Leading providers differ in their technical expertise, service scope, testing resources, and manufacturing partnerships. Matching these capabilities to a product’s needs, target market, timeline, and production volume can help identify a suitable development partner.
Blog Tags: